Takeda Pharmaceutical Company Limited (NYSE: TAK) is -4.67% lower on its value in year-to-date trading and has touched a low of $12.43 and a high of $20.00 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The TAK stock was last observed hovering at around $17.67 in the last trading session, with the day’s loss setting it -0.32% off its average median price target of $23.70 for the next 12 months. It is also 43.71% off the consensus price target high of $30.82 offered by 12 analysts, but current levels are 10.75% higher than the price target low of $19.44 for the same period.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
Currently trading at $17.35, the stock is -1.64% and -3.64% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.96 million and changing -1.81% at the moment leaves the stock -3.62% off its SMA200. TAK registered -7.66% loss for a year compared to 6-month loss of -8.25%. The firm has a 50-day simple moving average (SMA 50) of $17.73 and a 200-day simple moving average (SMA200) of $17.87.
The stock witnessed a 0.29% gain in the last 1 month and extending the period to 3 months gives it a -0.17%, and is -1.08% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 1.49% over the week and 2.02% over the month.
Current P/E ratio is 21.38 and Fwd P/E is 20.41. Distance from 52-week low is 39.58% and -13.25% from its 52-week high.
Takeda Pharmaceutical Company Limited (TAK) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Takeda Pharmaceutical Company Limited (TAK) is a “Buy”. 12 analysts offering their recommendations for the stock have an average rating of 2.00, where 2 rate it as a Hold and 1 think it is a “Overweight”. 9 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Takeda Pharmaceutical Company Limited is expected to release its quarterly report on 05/11/2021 and quarterly earnings per share for the current quarter are estimated at $0 with sales reaching $7.72M over the same period.The EPS is expected to grow by 484.60% this year, but quarterly earnings will post -0.80% year-over-year. Quarterly sales are estimated to shrink -99.00% in year-over-year returns.
Takeda Pharmaceutical Company Limited (TAK) Top Institutional Holders
355 institutions hold shares in Takeda Pharmaceutical Company Limited (TAK), with institutional investors hold 3.50% of the company’s shares. The shares outstanding are 3.15B, and float is at 3.13B with Short Float at 0.20%. Institutions hold 3.50% of the Float.
The top institutional shareholder in the company is Glenview Capital Management, LLC with over 15.26 million shares valued at $277.74 million. The investor’s holdings represent 0.48% of the TAK Shares outstanding. As of Dec 30, 2020, the second largest holder is Paulson & Company, Inc. with 11.3 million shares valued at $205.58 million to account for 0.36% of the shares outstanding. The other top investors are ARK Investment Management, LLC which holds 8.62 million shares representing 0.27% and valued at over $156.85 million, while Adelphi Capital LLP holds 0.24% of the shares totaling 7.58 million with a market value of $138.05 million.
Takeda Pharmaceutical Company Limited (TAK): Who are the competitors?
The company’s main competitors (and peers) include Johnson & Johnson (JNJ) that is trading 7.96% up over the past 12 months. Pfizer Inc. (PFE) is 1.21% up on the 1-year trading charts. Short interest in the company’s stock has fallen -22.62% from the last report on Dec 30, 2020 to stand at a total of 7.59 million short shares sold with a short interest ratio of 1.25.